- Home
- MYGN vs CRI Comparison
MYGN vs CRI Comparison
Compare MYGN & CRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CRI
- Stock Information
- Founded
- MYGN 1991
- CRI 1865
- Country
- MYGN United States
- CRI United States
- Employees
- MYGN N/A
- CRI N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CRI Apparel
- Sector
- MYGN Health Care
- CRI Consumer Discretionary
- Exchange
- MYGN Nasdaq
- CRI Nasdaq
- Market Cap
- MYGN 1.3B
- CRI 1.5B
- IPO Year
- MYGN 1995
- CRI 2003
- Fundamental
- Price
- MYGN $8.80
- CRI $42.08
- Analyst Decision
- MYGN Hold
- CRI Hold
- Analyst Count
- MYGN 15
- CRI 4
- Target Price
- MYGN $20.43
- CRI $49.00
- AVG Volume (30 Days)
- MYGN 875.3K
- CRI 1.7M
- Earning Date
- MYGN 05-06-2025
- CRI 04-25-2025
- Dividend Yield
- MYGN N/A
- CRI 7.60%
- EPS Growth
- MYGN N/A
- CRI N/A
- EPS
- MYGN N/A
- CRI 5.12
- Revenue
- MYGN $837,600,000.00
- CRI $2,844,102,000.00
- Revenue This Year
- MYGN $3.03
- CRI N/A
- Revenue Next Year
- MYGN $8.31
- CRI $0.35
- P/E Ratio
- MYGN N/A
- CRI $8.23
- Revenue Growth
- MYGN 11.21
- CRI N/A
- 52 Week Low
- MYGN $8.53
- CRI $38.84
- 52 Week High
- MYGN $29.30
- CRI $82.63
- Technical
- Relative Strength Index (RSI)
- MYGN 27.06
- CRI 46.24
- Support Level
- MYGN $8.53
- CRI $39.95
- Resistance Level
- MYGN $10.30
- CRI $42.70
- Average True Range (ATR)
- MYGN 0.44
- CRI 1.45
- MACD
- MYGN -0.01
- CRI 0.45
- Stochastic Oscillator
- MYGN 15.08
- CRI 83.94
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About CRI Carter's Inc.
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.